Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Sep;37(9):2910-2.
doi: 10.1128/JCM.37.9.2910-2912.1999.

Polymorphism of the human immunodeficiency virus type 1 (HIV-1) protease gene and response of HIV-1-infected patients to a protease inhibitor

P Bossi  1 , M Mouroux, A Yvon, F Bricaire, H Agut, J M Huraux, C Katlama, V Calvez
Affiliations

Polymorphism of the human immunodeficiency virus type 1 (HIV-1) protease gene and response of HIV-1-infected patients to a protease inhibitor

P Bossi et al. J Clin Microbiol. 1999 Sep.

Abstract

In order to analyze the impact of protease gene polymorphism on response to regimens containing a protease inhibitor, the entire protease coding domain from 58 human immunodeficiency virus type 1 (HIV-1)-infected patients who were protease inhibitor naive was sequenced before therapy was started. Plasma HIV-1 RNA levels were measured at baseline and at month 3 and month 6 after treatment. All patients were treated with a combination of two reverse transcriptase inhibitors and a protease inhibitor (saquinavir EOF [n = 28], ritonavir [n = 16], or indinavir [n = 14]). Before treatment, 30 different positions whose codons differed from the subtype B consensus sequence were observed. Major mutations associated with protease inhibitor resistance were not observed. No statistical correlation between the number of amino acid differences and the treatment efficacy at month 3 (-2.4 log) or month 6 (-2.7 log) was observed. At baseline, genotypic analysis of the HIV-1 protease gene of patients who have never received a protease inhibitor does not allow prediction of the efficacy of regimens containing a protease inhibitor.

PubMed Disclaimer

References

    1. Condra J H, Schleif W A, Blahy O M, Gabryelski L J, Graham D J, Quintero J C, Rhodes A, Robbins H L, Roth E, Shivaprakash M. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995;374:569–571. - PubMed
    1. Condra J H, Holder D J, Schleif W A, Blahy O M, Danovich R M, Gabryelski L J, Graham D J, Laird D, Quintero J C, Rhodes A, Robbins H L, Roth E, Shivaprakash M, Yang T, Chodakewitz J A, Deutsch P J, Leavitt R Y, Massari F E, Mellors J W, Squires K E, Steigbigel R T, Teppler H, Emini E A. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol. 1996;70:8270–8276. - PMC - PubMed
    1. Craig C, Race E, Sheldon J, Whittaker L, Gilbert S, Moffatt A, Rose S, Dissanayeke S, Chirn G-W, Duncan I B, Cammak N. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. AIDS. 1998;12:1611–1618. - PubMed
    1. Eberle J, Bechowsky B, Rose D, Hauser U, von der Helm K, Gurtler L, Nitschko H. Resistance of HIV type 1 to proteinase inhibitor RO 31-8959. AIDS Res Hum Retroviruses. 1995;11:671–676. - PubMed
    1. Flexner C. HIV-protease inhibitors. N Engl J Med. 1998;338:1281–1292. - PubMed

MeSH terms